A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
Launched by MERCK SHARP & DOHME LLC · Dec 11, 2023
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Has a diagnosis and stable medical management (for at least 3 months) of one of the following risk conditions for pneumococcal disease: Diabetes mellitus, chronic compensated liver disease, chronic lung disease, chronic heart disease, or chronic kidney disease.
- • Has completed pneumococcal conjugate vaccine regimen (PCV7, PCV10, or PCV13) at least 8 weeks before study enrollment.
- Exclusion Criteria:
- • Has previously received PPSV23 vaccine
- • Has a history of active hepatitis within 3 months before study vaccination
- • History of invasive pneumococcal disease within 3 years before study vaccination
About Merck Sharp & Dohme Llc
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., is a leading global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and vaccines that address unmet medical needs. With a strong focus on research and development, Merck Sharp & Dohme leverages advanced science and technology to enhance patient outcomes across various therapeutic areas, including oncology, infectious diseases, and cardiovascular health. Committed to ethical practices and regulatory compliance, the company actively engages in clinical trials to advance medical knowledge and improve health care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Caen, Calvados, France
Paris, , France
Lincoln, Nebraska, United States
Lincoln, Nebraska, United States
Lincoln, Nebraska, United States
Albuquerque, New Mexico, United States
Vestal, New York, United States
Greenville, South Carolina, United States
Spartanburg, South Carolina, United States
West Jordan, Utah, United States
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Madera, California, United States
Orlando, Florida, United States
Macon, Georgia, United States
Idaho Falls, Idaho, United States
Rexburg, Idaho, United States
Gulfport, Mississippi, United States
Lincoln, Nebraska, United States
Austin, Texas, United States
Brownsville, Texas, United States
Layton, Utah, United States
Chickasha, Oklahoma, United States
Desoto, Texas, United States
Mesquite, Texas, United States
Edogawa Ku, Tokyo, Japan
Hamilton, Ontario, Canada
Ankara, , Turkey
Montréal, Quebec, Canada
Miyazaki, , Japan
Ankara, , Turkey
Brownsville, Texas, United States
Quebec City, Quebec, Canada
Sarçam, Adana, Turkey
Kayseri, , Turkey
Colorado Springs, Colorado, United States
Turku, Varsinais Suomi, Finland
Yokohama, Kanagawa, Japan
Haebaru, Okinawa, Japan
Madrid, Madrid, Comunidad De, Spain
Leganés, Madrid, Spain
Madrid, , Spain
Sevilla, , Spain
Istanbul, , Turkey
Kokkola, Mellersta Osterbotten, Finland
Tampere, Pirkanmaa, Finland
Seinäjoki, Sodra Osterbotten, Finland
Espoo, Uusimaa, Finland
Esplugues De Llobregat, Barcelona, Spain
Santiago De Compostela, La Coruna, Spain
Barcelona, , Spain
Oulu, Pohjois Pohjanmaa, Finland
Saitama, , Japan
Bydgoszcz, Kujawsko Pomorskie, Poland
Solna, Stockholms Lan, Sweden
İzmir, , Turkey
Temuco, Araucania, Chile
Rionegro, Antioquia, Colombia
Montería, Cordoba, Colombia
Cali, Valle Del Cauca, Colombia
Cali, Valle Del Cauca, Colombia
Helsinki, Uusimaa, Finland
Bunkyo Ku, Tokyo, Japan
Lomianki, Mazowieckie, Poland
Badalona, Barcelona, Spain
Santiago, Region M. De Santiago, Chile
Santiago, Region M. De Santiago, Chile
Lille, Nord, France
Bydgoszcz, Kujawsko Pomorskie, Poland
Umeå, Vasterbottens Lan, Sweden
Mölndal, Vastra Gotalands Lan, Sweden
Halifax, Nova Scotia, Canada
Haifa, , Israel
Petah Tikva, , Israel
Miyazaki, , Japan
Okayama, , Japan
Pierrefonds, Quebec, Canada
Lodz, Lodzkie, Poland
Barcelona, Cataluna, Spain
Santiago, Region M. De Santiago, Chile
Tampa, Florida, United States
Jerusalem, , Israel
Bangkoknoi, Krung Thep Maha Nakhon, Thailand
Pathumwan, Krung Thep Maha Nakhon, Thailand
Blackfoot, Idaho, United States
Wroclaw, Dolnoslaskie, Poland
Santiago, Region M. De Santiago, Chile
Ratchathewi, Krung Thep Maha Nakhon, Thailand
Ankara, , Turkey
Louisville, Kentucky, United States
Lafayette, Louisiana, United States
Hastings, Nebraska, United States
Ottawa, Ontario, Canada
Montería, Cordoba, Colombia
Hat Yai, Songkhla, Thailand
Kayseri, , Turkey
Petah Tikva, , Israel
Hamilton, Ontario, Canada
Patients applied
Trial Officials
Medical Director
Study Director
Merck Sharp & Dohme LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported